Formula I CDK4/6 Inhibitors for Cell Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule CDK2/4/6 inhibitors are insufficient for effectively regulating cell cycle progression and gene transcription, particularly in controlling the entry of cells from the G1 phase to the S phase.
Innovation Solution
Development of compounds of Formula I, which include specific structural features such as various alkyl, haloalkyl, and aryl groups, and their pharmaceutically acceptable salts, solvates, or N-oxides, designed to inhibit CDK4 and CDK6, thereby regulating cell cycle progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule CDK2/4/6 inhibitors are used, then cell cycle regulation is attempted, but the inhibition effectiveness is insufficient
Solution Approach 1:
The patent modifies the molecular structure of CDK inhibitors by changing chemical parameters - introducing specific substituents (R1-R6 groups including alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, etc.) at defined positions in the core scaffold. This structural parameter change optimizes the inhibitor's binding affinity and functional effectiveness against CDK4/6, resolving the insufficiency of existing inhibitors.
Solution Approach 2:
The invention creates composite molecular structures by combining a core CDK inhibitor scaffold with various substituent groups (R1-R6). These composite structures allow the molecule to achieve both high binding affinity to CDK4/6 and favorable pharmacological properties, thereby improving inhibition effectiveness while maintaining cell cycle control capability.
2Reliability
If CDK4/6 inhibition is strengthened, then cell cycle progression is better controlled, but structural complexity increases
Solution Approach 1:
The patent divides the molecular structure into a core inhibitor scaffold and separate substituent groups (R1-R6). This segmentation allows systematic optimization of binding affinity through the core structure while managing overall complexity through modular substituents. Each substituent can be independently selected and optimized without redesigning the entire molecule.
Solution Approach 2:
The invention applies different substituent types (R1-R6) to specific positions in the molecular structure based on local requirements. For example, electron-withdrawing or electron-donating groups are placed at positions that optimize binding to specific residues in the CDK4/6 active site, while maintaining overall structural manageability through localized modifications rather than global complexity.
Data Source
AI summary
The disclosure is directed to compounds of Formula IPharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.